PARP1 and cancer: Our current understanding of the downstream effects of PRMT5 inhibition include the impairment of pre-mRNA splicing and DNA damage repair, co-treatment of cancers with agents that target these pathways such as PARP inhibitors and chemotherapy, is potentially synergistic.